J&J Unit Hit With Antitrust Suit Over 'Sham' Zytiga Patent
Law360 (May 21, 2019, 8:59 PM EDT) -- The city of Baltimore has filed a proposed class action antitrust case against the Johnson & Johnson unit that makes the prostate cancer drug Zytiga, alleging the company filed "sham" lawsuits against potential generic competitors over a patent it knew was invalid.
The suit, filed Thursday in the Eastern District of Virginia, seeks to represent everyone in the country who purchased Zytiga at a higher price because generic versions were kept off the market due to the infringement suits by Janssen Biotech.
Baltimore officials said in a statement Monday that the city's self-insured prescription drug plan, which pays for prescription drugs...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!